Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2012. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share acquisition details related to dividend reinvestment.
- Share Price: 1,473.5 pence per Ordinary Share and $46.05 per ADS.
- Transaction Type: Re-investment of dividends paid on July 5, 2012.
Material Changes
The filing details increases in notional interests in Ordinary Shares and American Depositary Shares (ADSs) for various executives. These changes resulted from the reinvestment of dividends and include both personal contributions and company matching contributions under the Deferred Annual Bonus Plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document notes that notional dividends accrued will be paid out based on the vesting percentage of deferred annual bonus holdings following a three-year measurement period.
Investor Verification Points
- Verify the total number of shares acquired by Sir Andrew Witty (2,540 Ordinary Shares total) and other named executives.
- Confirm the dividend reinvestment price of 1,473.5 pence per Ordinary Share.
- Review the vesting schedule and conditions for the 2009 Deferred Annual Bonus Plan to understand future payout obligations.